Drug Type TCR-T Cell therapy |
Synonyms 821 TCR, 821TCR |
Action modulators, inhibitors |
Mechanism HLA class I antigen modulators, KKLC1 inhibitors(Kita-Kyushu lung cancer antigen-1 inhibitors) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhaseDiscontinuedPreclinical |
First Approval Date- |
Regulation- |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Solid tumor | Preclinical | United States | 13 Feb 2023 |





